Cutting-Edge Oncology Drugs

Breakthrough Therapies for Cancer Treatment

Oxford Target Therapeutics (OTT) is a pioneering pharmaceutical company focused on advancing innovative cancer therapies. We specialise in identifying and developing novel drug candidates that target crucial cellular processes involved in cancer progression. Our mission is to bridge the gap between cutting-edge research and transformative cancer treatments, empowering hope for patients facing this challenging disease.

short video

Drug Development

OTT excels in translating scientific discoveries into viable cancer therapeutics. We navigate the complex drug development process, optimising efficacy, safety, and commercial potential for breakthrough cancer medicines.

Transforming Innovation

OTT specialises in addressing unmet medical needs in oncology, with a key focus on difficult-to-treat cancers. Our mission is to develop novel solutions that bring hope to patients and improve their quality of life.

Experienced Team

OTT is led and supported by a diverse team with complementary expertise from the medical sciences with long academic and industrial research experience as well as from the pharmaceutical industry and the capital markets.

The Persistent Battle Against Cancer

As one of the leading causes of death globally, cancer remains a pressing and challenging healthcare issue affecting millions of individuals worldwide. Cancer is characterised by the uncontrolled growth and division of abnormal cells, leading to the formation of tumours or the invasion of healthy tissues. This devastating disease manifests in various forms, impacting numerous organs and systems, resulting in significant physical and emotional hardships for patients and their loved ones.

.

2300000

Breast Cancer new cases each year

1800000

deaths annually from Lung Cancer

1400000

Prostate Cancer new cases each year

200000

$ million Cancer drug sales each year

Empowering Breakthroughs in Cancer Therapies

Experience the Future of Oncology Innovation

First-in-Class Cancer Therapeutics

Cutting-edge APC/C-targeting therapies with high potential for clinical success.

Addressing Global Cancer Challenges

Targeting pressing unmet needs in oncology, offering hope and improved outcomes.

Strategic Collaborations & Licensing

Exciting partnerships for accelerated drug development and widespread accessibility.

Investing in Transformative Cancer Solutions

Embrace the untapped potential of OTT's transformative cancer therapies, driving unparalleled medical advancements and improved patient lives.

TNBC

Triple Negative Breast Cancer is an aggressive form of breast cancer characterised by the absence of oestrogen receptor, progesterone receptor, and HER2 expression.

CRC

Colorectal Cancer CRC) is a malignancy affecting the colon or rectum, with high morbidity and mortality rates due to treatment resistance and disease recurrence.

NSCLC

Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85% of all cases. Many NSCLC patients develop resistance.

MM

Multiple Myeloma (MM) is a blood malignancy characterised by the abnormal proliferation of plasma cells in the bone marrow. It remains an incurable disease.

SCCHN

Squamous Cell Carcinoma of the Head and Neck (SCCHN) is a highly prevalent and aggressive form of cancer that affects various regions of the head and neck.

UC

Bladder Cancer / Urothelial Carcinoma (UC), is the most common type of bladder cancer with has a high recurrence rate and can affect other parts of the urinary system.

Inter-disciplinary capabilities

Oxford Target Therapeutics is committed to pushing the boundaries of innovation by fostering multidisciplinary research collaborations. We actively engage with leading companies, universities, and research institutions to leverage diverse expertise, capitalise on collaboration opportunities, and drive advancements in cancer drug development. Additionally, our strategic partnerships enable us to access specialised resources and capabilities through Contract Research Organizations (CROs), ensuring efficient and effective progress in our drug development programs.

Learn more

Ignite the Sparks of Innovation

Cancer Masterminds: Pioneering Breakthroughs

Embrace the Future of Oncology Innovation. Accelerate breakthrough cancer therapies by partnering with OTT, at the forefront of pioneering drug discovery and development. Investors and pharma companies, seize the opportunity to access transformative oncology solutions and unlock unparalleled potential for global success. Unleash the Full Potential of Brilliant Minds.

Learn more